05.22.15
EMD Millipore, the Life Science business of Merck KGaA, and Singulex, a developer and provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, have entered a definitive agreement under which EMD Millipore will control and manage the Singulex Life Science Research business.
Singulex will receive an upfront payment, royalties and additional payments based on certain commercial milestones. EMD Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications. Financial terms were not disclosed.
The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection. The clinical benefits have been well-established and Singulex will continue to operate a large clinical service business based on novel, enabling SMC assays.
"This agreement is further evidence of EMD Millipore's commitment to bringing innovative technologies to our global life science customers," said Udit Batra, president and chief executive officer of EMD Millipore. "The Erenna platform offers the unique advantage of unrivaled sensitivity and precision and will be a strong addition to our Protein Detection franchise."
Singulex will receive an upfront payment, royalties and additional payments based on certain commercial milestones. EMD Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications. Financial terms were not disclosed.
The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection. The clinical benefits have been well-established and Singulex will continue to operate a large clinical service business based on novel, enabling SMC assays.
"This agreement is further evidence of EMD Millipore's commitment to bringing innovative technologies to our global life science customers," said Udit Batra, president and chief executive officer of EMD Millipore. "The Erenna platform offers the unique advantage of unrivaled sensitivity and precision and will be a strong addition to our Protein Detection franchise."